1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The general aim of this study is to compare telmisartan 80 mg with valsartan 160 mg in hypertensive patients with type 2 diabetes and overt nephropathy with adjusted blood pressure beyond the target of 130/80 mmHg after one year of treatment.
The primary objective of this study is to show that telmisartan 80 mg is at least as effective (i.e., not inferior) and possibly superior to valsartan 160 mg in reducing 24 hour proteinuria after one year of treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Nephropathies Hypertension |
Drug: Telmisartan Drug: Valsartan |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy |
- Change from baseline (Visit 6) in 24 hour proteinuria, after one year of treatment (study end) with telmisartan 80 mg versus valsartan 160 mg.
- Change from baseline in 24 hour albuminuria, creatinine clearance, estimated GFR, serum creatinine, 24 hour sodium excretion, ADMA, 8-iso-prostaglandin F2a, hs CRP, doubling of serum creatinine, composite of cardiovascular morbidity and mortality.
| Estimated Enrollment: | 885 |
| Estimated Study Completion Date: | December 2005 |
This is a randomised, double-blind, double-dummy, forced titration, multicentre, parallel group trial in patients with essential hypertension, diabetes mellitus type 2 and diabetic nephropathy.
After a 4-6 week Run-in period, patients are randomised to one of the treatment groups and receive either Telmisartan 40 - 80 mg or Valsartan 80 - 160 mg. The treatment regimen is a forced titration with the lower dose given for 2 weeks and the higher dose given for the rest of the treatment period summing up to 52 weeks of treatment. During the treatment period, 8 visits to the investigator are scheduled in order to control blood pressure, renal function parameters and safety. In addition, parameters of endothelial function and oxidative stress are measured at baseline, 6 months and after one year of treatment.
Study Hypothesis:
Non-inferiority of telmisartan 80 mg compared to valsartan 160 mg will be tested using the following set of hypotheses:
Null Hypothesis:
The overall mean change from baseline in UPER (24 hour urinary protein excretion rate) for telmisartan 80 mg is inferior to that for valsartan 160 mg by 0.5 g/day or more.
Alternative Hypothesis:
The overall mean change from baseline in UPER (24 hour urinary protein excretion rate) for telmisartan 80 mg is less than 0.5 g/day worse than that for valsartan 160 mg.
Comparison(s):
In order to test the non-inferiority hypothesis, analysis of covariance with treatment and centre as main effects and baseline as a covariate will be performed. Time-to-event data will be analysed using the log-rank test.
Eligibility| Ages Eligible for Study: | 30 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Type 2 diabetes mellitus
- Aged 30-70 years of age
Hypertension at screening defined as:
- an average cuff systolic blood pressure > 130 mmHg and/or diastolic blood pressure >80 mmHg in untreated patients OR
- patients receiving antihypertensive therapy (i.e., medications specifically prescribed to treat hypertension)
- Overt nephropathy defined by 24 hour proteinuria >= 900 mg and by serum creatinine below 265 mol/l (3.0 mg/dl)
Exclusion Criteria: None
Contacts and Locations
Hide Study Locations| Czech Republic | |
| University Hospital St. Anna | |
| Brno, Czech Republic, 656 91 | |
| University Hospital Hradec Kralove | |
| Hradec Kralove, Czech Republic, 500 05 | |
| University Hospital Vihohrady | |
| Prague 10, Czech Republic, 100 34 | |
| General University Hospital | |
| Prague 2, Czech Republic, 128 08 | |
| District Hospital Tabor | |
| Tabor, Czech Republic, 390 03 | |
| Masaryk Hospital | |
| Usti nad Labem, Czech Republic, 401 13 | |
| Hospital Usti nad Orlici | |
| Usti nad Orlici, Czech Republic, 562 18 | |
| Denmark | |
| Medical Department | |
| Copenhagen NV, Denmark, DK-2400 | |
| Medicinsk afdeling | |
| Fredericia, Denmark, DK-7000 | |
| Medicinsk afdeling F, Endokrinologisk | |
| Hiller?d, Denmark, 3400 | |
| Endokrinologisk afdeling | |
| Hvidovre, Denmark, DK-2650 | |
| Medical Department | |
| Roskilde, Denmark, DK-4000 | |
| France | |
| Chu Sud | |
| Amiens, France, 80054 | |
| Centre Hospitalier | |
| Beauvais, France, 60021 | |
| Hopital Duchenne | |
| Boulogne sur Mer cedex, France, 62320 | |
| Hopital Clemenceau | |
| Caen cedex 5, France, 14033 | |
| Centre Hospitalier | |
| Dunkerque, France, 59240 | |
| Hopital Albert Michalon | |
| La Tronche, France, 38700 | |
| Hopital A.Mignot | |
| Le Chesnay, France, 78157 | |
| Hopital Maison Blanche | |
| Reims, France, 51100 | |
| Hopital Yves Le Foll | |
| Saint Brieuc cedex 1, France, 22023 | |
| Hopital Saint Quentin | |
| Saint Quentin, France, 02100 | |
| Centre Hospitalier | |
| Valenciennes, France, 59322 | |
| Germany | |
| Boehringer Ingelheim Investigational Site | |
| Aschaffenburg, Germany, 63739 | |
| Diabetes Klinik Bad Mergentheim | |
| Bad Mergentheim, Germany, 97980 | |
| Charite Campus Buch | |
| Berlin, Germany, 13125 | |
| Institut fur Klinische Forschung | |
| Berlin, Germany, 10115 | |
| KFH Dialysezentrum | |
| Eberswalde, Germany, 16225 | |
| Universitatsklinik Heidelberg | |
| Heidelberg, Germany, 69115 | |
| Boehringer Ingelheim Investigational Site | |
| Karlsruhe, Germany, 76133 | |
| Institut fur Klinische Forschung | |
| Mainz, Germany, 55116 | |
| Boehringer Ingelheim Investigational Site | |
| Munster, Germany, 48145 | |
| Boehringer Ingelheim Investigational Site | |
| Neuwied, Germany, 56564 | |
| Boehringer Ingelheim Investigational Site | |
| Pirna, Germany, 01796 | |
| Boehringer Ingelheim Investigational Site | |
| Riesa, Germany, 01587 | |
| Boehringer Ingelheim Investigational Site | |
| Rosenheim, Germany, 83022 | |
| Boehringer Ingelheim Investigational Site | |
| Saarbrucken, Germany, 66121 | |
| Boehringer Ingelheim Investigational Site | |
| Saarlouis, Germany, 66740 | |
| Boehringer Ingelheim Investigational Site | |
| Sinsheim, Germany, 74889 | |
| Boehringer Ingelheim Investigational Site | |
| Speyer, Germany, 67346 | |
| Internist | |
| Wurzburg, Germany, 97072 | |
| Italy | |
| Azienda Ospedaliera Policlinico S. Orsola Malpighi | |
| Bologna, Italy, 40138 | |
| Ospedali Riuniti di Livorno | |
| Livorno, Italy, 57100 | |
| Presidio Ospedaliero Campo di Marte | |
| Lucca, Italy, 55100 | |
| Universita degli Studi "Federico II" | |
| Napoli, Italy, 80131 | |
| Azienda Ospedaliera di Padova | |
| Padova, Italy, 35128 | |
| IRCCS Policlinico S.Matteo | |
| Pavia, Italy, 27100 | |
| Policlinico Monteluce | |
| Perugia, Italy, 06100 | |
| Azienda Ospedaliera S. Maria degli Angeli | |
| Pordenone, Italy, 33170 | |
| Ospedale "S. Maria delle Croci" | |
| Ravenna, Italy, 48100 | |
| Universita Tor Vergata | |
| Roma, Italy, 00133 | |
| Korea, Republic of | |
| Keimyung University Dongsan Medical Center | |
| Daegu, Korea, Republic of, 700712 | |
| Yonsei University Medical Center | |
| Seoul, Korea, Republic of | |
| Malaysia | |
| Hospital Ipoh | |
| Ipoh, Perak, Malaysia, 30990 | |
| University Sains Malaysia | |
| Kelantan, Malaysia, 16150 | |
| University Malaya Medical Centre | |
| Kuala Lumpur, Malaysia, 59100 | |
| Hospital Kuala Lumpur | |
| Kuala Lumpur, Malaysia, 50586 | |
| Penang General Hospital | |
| Penang, Malaysia | |
| Hospital Putrajaya | |
| Selangor, Malaysia | |
| Portugal | |
| Centro Hospitalar de Coimbra | |
| Coimbra, Portugal, 3041.853 | |
| Hospital Distrital de Faro | |
| Faro, Portugal, 8000-386 | |
| Hospital de Santa Maria | |
| Lisboa, Portugal, 1169-024 | |
| Hospital de Santa Marta | |
| Lisboa, Portugal, 1169-024 | |
| Associac?o Protectora dos Diabeticos de Portugal | |
| Lisboa, Portugal, 1250 | |
| Hospital Curry Cabral | |
| Lisbon, Portugal, 1050-035 | |
| Hospital Pedro Hispano | |
| Matosinhos, Portugal, 4460-301 | |
| Hospital de S. Jo?o | |
| Porto, Portugal, 4200 | |
| Centro Hospitalar Vila Nova de Gaia | |
| Vila Nova de Gaia, Portugal, 4434-502 | |
| Russian Federation | |
| Russian State Medical University | |
| Moscow, Russian Federation, 117485 | |
| Russian State Medical University | |
| Moscow, Russian Federation, 115516 | |
| Russian State Medical University | |
| Moscow, Russian Federation, 107066 | |
| President's Medical Center | |
| Moscow, Russian Federation, 121356 | |
| Medical Academy named Sechenova I.M. | |
| Moscow, Russian Federation, 103030 | |
| Regional Clinical Scientific Research Institute | |
| Moscow, Russian Federation, 129110 | |
| Russian Cardiology Research Center | |
| Moscow, Russian Federation, 121552 | |
| National Endocrinology Research Center of Russia | |
| Moscow, Russian Federation, 117036 | |
| Russian Academy for Advanced Medical Studies | |
| Moscow, Russian Federation, 125315 | |
| Moscow President's Medical Center | |
| Moscow, Russian Federation, 129090 | |
| City Hospital of Saint Elizaveta | |
| St. Petersburg, Russian Federation, 195257 | |
| Military Medical Academy | |
| St. Petersburg, Russian Federation, 198013 | |
| Slovakia | |
| NovaMed | |
| Banska Bystrica, Slovakia, 974 05 | |
| Faculty Hospital of L. Derer | |
| Bratislava, Slovakia, 833 05 | |
| Ministry Hospital of Internal Affairs | |
| Bratislava, Slovakia, 812 72 | |
| Faculty Hospital | |
| Bratislava, Slovakia, 81369 | |
| Diabetologic and Internal Clinic | |
| Lucenec, Slovakia, 984 01 | |
| Faculty Hospital | |
| Nitra, Slovakia, 94901 | |
| Hospital Nove Mesto | |
| Nove Mesto, Slovakia, 915 01 | |
| Regional Hospital Nove Zamky | |
| Nove Zamky, Slovakia, 940 52 | |
| MSP-DIAGNOSTIK, Ltd. | |
| Trencin, Slovakia, 91101 | |
| Faculty Hospital Trnava | |
| Trnava, Slovakia, 91701 | |
| Spain | |
| Hospital Torrecardenas | |
| Almeria, Spain, 04009 | |
| Hospital Ntra. Sra de Sonsoles | |
| Avila, Spain, 05071 | |
| Hospital Clinico y Provincial de Barcelona | |
| Barcelona, Spain, 08036 | |
| Hospital Vall d'Hebron | |
| Barcelona, Spain, 08038 | |
| Hospital de Basurto | |
| Bilbao, Spain, 48013 | |
| Hospital Universitario Reina Sofia | |
| Cordoba, Spain, 14004 | |
| Hospital de Cabuenes | |
| Gijon, Spain, 33204 | |
| Hospital Virgen del Rocio | |
| Sevilla, Spain, 41013 | |
| Hospital Universitario La Fe | |
| Valencia, Spain, 46009 | |
| Taiwan | |
| Changhua Christian Hospital | |
| Changhua, Taiwan, 500 | |
| Buddhist Tzu Chi Hospital | |
| Hualien City, Taiwan, 970 | |
| National Cheng Kung University Hospital | |
| Tainan, Taiwan, 70428 | |
| Mackay Memorial Hospital | |
| Taipei, Taiwan, 104 | |
| Chi Mei Medical Center | |
| Taiwan, Taiwan, 701 | |
| Ukraine | |
| Dnyepropyetrovsk Medical Academy | |
| Dnyepropetrovsk, Ukraine, 49044 | |
| Institute of Diabetic pathology problems | |
| Kharkov, Ukraine, 61070 | |
| Kharkiv Medical State University | |
| Kharkov, Ukraine, 61022 | |
| V.P. Komisarenko Institute of Endocrinology and Metabolism | |
| Kiev, Ukraine, 04114 | |
| Institute of Cardiology | |
| Kiev, Ukraine, 03151 | |
| Kyiv Clinical Hospital No. 1 | |
| Kyiv, Ukraine, 02091 | |
| Zaporozhye Regional Clinical Hospital | |
| Zaporozhye, Ukraine, 69600 | |
| Study Chair: | Boehringer Ingelheim Study Coordinator | B.I. Pharma GmbH & Co. KG |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00153023 History of Changes |
| Other Study ID Numbers: | 502.396 |
| Study First Received: | September 9, 2005 |
| Last Updated: | May 18, 2012 |
| Health Authority: | Spain: Ministry of Health Germany: BfArM Austria: SUKL (state institute for drug control) South Africa: Medicines Control Council Denmark: Danish Medicines Agency France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Italy: Ethics Committee Portugal: INFARMED Taiwan: Department of Health Austria: Ministry of Health Crae of Ukraine (MoH of Ukraine) South Korea: Korea Food and Drug Administration (KFDA) Malaysia: Ministry of Health, National Pharmaceutical Control Bureau (NPCB), 6 main ECs |
Additional relevant MeSH terms:
|
Diabetic Nephropathies Hypertension Kidney Diseases Urologic Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Vascular Diseases Cardiovascular Diseases Valsartan Telmisartan |
Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Protease Inhibitors Enzyme Inhibitors |
ClinicalTrials.gov processed this record on June 17, 2013